IRIDEX CORP — fact timeline

IRIDEX CORP reported first quarter ended April 4, 2026 results: revenue $11.8 million, net income $0.5 million or $0.03 per share, EPS $0.03 per share. Guidance reaffirmed.

“glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026. First Quarter 2026 Financial Highlights • Generated total revenue of $11.8 million, compared to $11.9 million in the prior year period • Cyclo G6® product family revenue was $3.6 million, representing growth of 14% year-over-year compared to $3.2 million in the”

IRIDEX CORP reported FY 2026 results: revenue $51 million to $53 million.

“The Company currently forecasts 2026 revenue of between $51 million and $53 million.”

IRIDEX CORP reported Full year 2025 (year ended January 3, 2026) results: revenue $52.7 million, net income Net loss for 2025 improved to $4.4 million, EPS $0.26 per share.

“Revenue for the year ended January 3, 2026 was $52.7 million, representing growth of 8% compared to $48.7 million in 2024.”

IRIDEX CORP reported Q4 2025 (three months ended January 3, 2026) results: revenue $14.7 million, net income Net loss was $0.2 million, EPS $0.01 per share.

“Revenue for the three months ended January 3, 2026 was $14.7 million, representing a 16% year-over-year increase compared to the fourth quarter of 2024.”

IRIDEX CORP entered into Lease with SFIII Hellyer, LLC and SFIII FOS Hellyer Holding, LLC valued at approximately $646,464 (effective 2026-03-09).

“On March 9, 2026, IRIDEX Corporation (the “Company”) and SFIII Hellyer, LLC and SFIII FOS Hellyer Holding, LLC (the “Landlord”) entered into a triple net lease (the “Lease”)”

IRIDEX CORP: Stockholders approved amendment and restatement of the Amended and Restated Certificate of Incorporation to modernize the charter, increase authorized common shares from 30,000,000 to 63,500,000, and establish designations of preferred stock including Series B Preferred Stock (effective 2025-06-11).

“At the Annual Meeting, the Company’s stockholders approved an amendment and restatement of the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to, among other matters: modernize the Charter, increase the number of authorized shares of the Company’s common stock from 30,000,000 to 63,500,000 shares, and establish the designations, powers, preferences and relative and other special rights and the qualifications, limitations and restrictions of the preferred stock, including the Company’s Series B Preferred Stock, par value $0.01 per share (the “Restated Charter”) (the “Restated Charter Proposal”).”

IRIDEX CORP received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). As described in the Notice, the Company’s last reported stockholders’ equity as of March 29, 2025, was approximately $852,000 and, as of May 14, 2025, the Company does not meet the alternative listing requirements of its market value of listed securities or its net income from continuing operations in”

Kenneth E. Ludlum resigned as Director at IRIDEX CORP.

“Kenneth E. Ludlum has agreed to resign and has submitted his resignation to the Company’s Board and all committees thereof, effective as of April 7, 2025.”

Robert E. Grove resigned as Director at IRIDEX CORP.

“Robert E. Grove has agreed to resign and has submitted his resignation to the Company’s Board and all committees thereof, effective as of April 2, 2025.”

IRIDEX CORP incurred convertible notes of $4,000,000 with Novel Inspiration International Co., Ltd..

“an initial convertible promissory note in an aggregate principal amount of $4,000,000”

Fuad Ahmad departed as Chief Financial Officer at IRIDEX CORP.

“Romeo Dizon was appointed by the Company’s Board as its Chief Financial Officer, to replace Fuad Ahmad effective as of the Closing”

Romeo Dizon was appointed as Chief Financial Officer at IRIDEX CORP.

“Romeo Dizon was appointed by the Company’s Board as its Chief Financial Officer, to replace Fuad Ahmad effective as of the Closing”

Nick Chen was appointed as Director at IRIDEX CORP.

“the Company’s board of directors (the “Board”) appointed William Moore and Nick Chen as members of the Board, effective as of the Closing”

William Moore was appointed as Director at IRIDEX CORP.

“the Company’s board of directors (the “Board”) appointed William Moore and Nick Chen as members of the Board, effective as of the Closing”

Patrick Mercer was appointed as Director at IRIDEX CORP.

“On November 22, 2024, the board of directors (the “Board”) of IRIDEX Corporation (the “Company”) appointed Patrick Mercer, the Company’s current President, Chief Executive Officer and Chief Operating Officer, to serve as a member of the Board, with an initial term expiring at the Company’s 2025 annual meeting of stockholders, effective immediately.”

David Bruce resigned as Director at IRIDEX CORP.

“on November 22, 2024, Mr. Bruce resigned from the Board, effective immediately.”

David Bruce was terminated as Chief Executive Officer at IRIDEX CORP.

“On October 1, 2024, Dave Bruce was terminated as the Company’s Chief Executive Officer and principal executive officer, effective immediately, and on November 22, 2024, Mr. Bruce resigned from the Board, effective immediately.”

David Bruce resigned as Director at IRIDEX CORP.

“on November 11, 2024, Mr. Bruce resigned from the Board.”

David Bruce was terminated as Chief Executive Officer at IRIDEX CORP.

“On October 1, 2024, Dave Bruce was terminated as the Company’s Chief Executive Officer (the “CEO”) and principal executive officer, effective immediately”

Scott Shuda was appointed as Executive Chairperson at IRIDEX CORP.

“On October 1, 2024, the Board appointed Scott Shuda as the Board’s Executive Chairperson, effective as of such date.”

David I. Bruce changed role as Chief Executive Officer at IRIDEX CORP.

“replacing David I. Bruce in such roles”

Patrick Mercer was appointed as Chief Executive Officer at IRIDEX CORP.

“On October 1, 2024, the board of directors (the “Board”) of IRIDEX Corporation (the “Company”) appointed Patrick Mercer as its Chief Executive Officer and designated Mr. Mercer as the Company’s principal executive officer for purposes of the rules and regulations of the Securities and Exchange Commission (the “SEC”), effective as of such date, replacing David I. Bruce in such roles.”

Patrick Mercer was appointed as President at IRIDEX CORP.

“On May 22, 2024, the board of directors (the “Board”) of IRIDEX Corporation(the “Company”) appointed Patrick Mercer as its President, effective as of such date.”

IRIDEX CORP reported first quarter ended March 30, 2024 results: revenue $11.8 million, net income $3.5 million, EPS $0.21 per share.

“today reported financial results for the first quarter ended March 30, 2024, and provided a business update. First Quarter 2024 Financial Highlights • Generated total revenue of $11.8 million, compared to $13.7 million in the prior year period • Cyclo G6® product family revenue in the first quarter of $3.0 million, compared to $3.7 million in the prior year period o”

IRIDEX CORP reported the year ended December 30, 2023 results: revenue $51.9 million.

“Revenue for the year ended December 30, 2023 was $51.9 million compared to $57.0 million in 2022.”

IRIDEX CORP reported the fourth quarter ended December 30, 2023 results: revenue $12.5 million, net income Net loss for the fourth quarter of 2023 was $3.0 million, EPS $0.18 per share.

“Revenue for the three months ended December 30, 2023 was $12.5 million compared to $15.2million during the same period of the prior year. Retina product revenue decreased 7% compared to the prior year period to $7.5 million. Total product revenue from the Cyclo G6 glaucoma product group was $3.0 million, a decrease of $1.2 million versus the fourth quarter of 2022. Other revenue decreased to $2.0 million in the fourth quarter of 2023 compared to the prior year period of $2.9 million, primarily driven by decreased royalties due to expiration of licensed patents and lower service revenue. Fourth quarter revenue was impacted by several factors. In the retina business, deferral of capital purchases led to lower system sales in the U.S. and internationally, international distributors destocked inventory in advance of new laser platform launches and to minimize any potential impact from transactions resulting from Iridex’s strategic review. The Company experienced isolated supply chain limit”

IRIDEX CORP reported third quarter ended September 30, 2023 results: revenue $12.9 million, net income $1.8 million, or $0.11 per share, EPS $0.11 per share.

“diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. Recent Business Updates • Generated total revenue of $12.9 million, representing flat sequential quarter revenue and a decrease of 12% year-over-year • Cyclo G6® product family revenue in the third quarter of $3.0 million, representing a”

IRIDEX CORP reported full year 2023 results: revenue $55 million to $57 million. Guidance lowered.

“With lower than expected probe unit sales growth and capital equipment softness in the first half of the year , the Company is updating its full year 2023 expectations as follows: Cyclo G6 probe sales of 61,000 to 63,000 units representing approximately 1% to 5% growth over 2022 and Cyclo G6 systems installed base expansion of 210 to 230 systems. Total revenue for the full year is expected to be $55 million to $57 million, representing flat to 3% growth year-over-year, after adjusting for approximately $1.5 million reduction in royalty revenue.”

IRIDEX CORP reported second quarter ended July 1, 2023 results: net income $2.8 million, EPS $0.17 per share.

“Revenue for the three months ended July 1, 2023 was $12.9 million compared to $13.8 million during the same period of the prior year.”

IRIDEX CORP shareholders rejected To approve of the amendment to the Amended and Restated Certificate of Incorporation to eliminate or limit the personal liability of officers..

“Proposal 5: To approve of the amendment to the Amended and Restated Certificate of Incorporation to eliminate or limit the personal liability of officers. For Against Abstain Broker Non-Votes 5,231,977 1,445,031 7,042 3,259,293”

IRIDEX CORP shareholders approved To approve of the 2008 Equity Incentive Plan, as amended..

“Proposal 4: To approve of the 2008 Equity Incentive Plan, as amended. For Against Abstain Broker Non-Votes 5,387,400 1,132,190 164,460 3,259,293”

IRIDEX CORP shareholders approved To conduct an advisory vote to approve the compensation of the Company’s named executive officers..

“Proposal 3: To conduct an advisory vote to approve the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 5,688,229 830,659 165,162 3,259,293”

IRIDEX CORP shareholders approved To ratify the appointment of BPM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 30, 2023. at the 2023-12-30 meeting.

“Proposal 2: To ratify the appointment of BPM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 30, 2023. For Against Abstain Broker Non-Votes 9,631,991 290,323 21,029 0”

IRIDEX CORP shareholders approved Election of Directors.

“Proposal 1: Election of Directors. Nominee For Against Abstain Broker Non-Votes David I. Bruce 5,989,369 684,641 10,040 3,259,293 Nandini Devi 5,466,465 1,096,587 120,998 3,259,293 Robert Grove, Ph.D. 5,445,151 1,117,916 120,983 3,259,293 Beverly A. Huss 5,810,909 595,101 278,040 3,259,293 Kenneth E. Ludlum 5,301,969 1,095,579 286,502 3,259,293 Scott Shuda 5,556,058 867,379 260,613 3,259,293”

IRIDEX CORP reported full year 2023 results: revenue $57 million to $59 million. Guidance reaffirmed.

“Total revenue for the full year is expected to be $57 million to $59 million.”

IRIDEX CORP reported first quarter ended April 1, 2023 results: revenue $13.7 million, net income $2.1 million, EPS $0.13 per share.

“Revenue for the three months ended April 1, 2023 was $13.7 million compared to $13.4 million during the same period of the prior year.”

IRIDEX CORP reported full year 2023 results: revenue $57 million to $59 million. Guidance initiated.

“Total revenue for the full year is expected to be $57 million to $59 million.”

IRIDEX CORP reported the year ended December 31, 2022 results: revenue $57.0 million, net income $7.5 million, EPS $0.47 per share.

“577 systems in February 2023 • Cash and cash equivalents totaled approximately $13.9 million as of December 31, 2022 Full Year 2022 Highlights • Generated total revenue of $57.0 million, an increase of 6% compared to 2021 • Cyclo G6 product family revenue of $14.7 million, an increase of 5% year-over-year • Sold 59,800 Cyclo G6 probes, compared to 58,200 in the”

IRIDEX CORP reported the three months ended December 31, 2022 results: revenue $15.2 million, net income $1.1 million, EPS $0.07 per share.

“results for the fourth quarter and year ended December 31, 2022 and issued 2023 financial guidance. Fourth Quarter 2022 & Recent Highlights • Generated total revenue of $15.2 million, essentially unchanged from the prior year period • Cyclo G6® product family revenue of $4.2 million, an increase of 9% year-over-year o 16,400 Cyclo G6 probes sold, a quarterly”

IRIDEX CORP reported the full fiscal year ended December 31, 2022 results: revenue between $56.9 million and $57.1 million.

“Total revenue is expected to be between $56.9 million and $57.1 million, with the midpoint representing growth of 6% compared to $53.9 million in 2021”

IRIDEX CORP reported the fourth fiscal quarter ended December 31, 2022 results: revenue between $15.1 million and $15.3 million.

“Total revenue is expected to be between $15.1 million and $15.3 million, unchanged compared to last year's fourth quarter”

IRIDEX CORP reported fiscal year 2022 results: revenue $56 million to $58 million. Guidance reaffirmed.

“Iridex continues to expect total revenue for fiscal year 2022 to range from $56 million to $58 million, reflecting growth of 4% to 8% over fiscal year 2021.”

IRIDEX CORP reported the third quarter ended October 1, 2022 results: revenue $14.6 million, net income $1.8 million, EPS $0.11 per share.

“the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 1, 2022. Third Quarter 2022 Highlights • Total revenue of $14.6 million, a record third quarter revenue, and an increase of 10% over the prior year period • Gross Margin was 44.1% compared to 43.6% in the prior year period • Cyclo G6® product family”

Beverly A. Huss was appointed as Director at IRIDEX CORP.

“On March 17, 2022, Iridex Corporation (the “ Company ”) appointed Beverly A. Huss to its board of directors (the “ Board ”), effective March 17, 2022 (the “ Effective Date ”).”